BioLife Solutions Inc
NASDAQ:BLFS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (10), the stock would be worth $20.52 (4% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10.4 | $21.38 |
0%
|
| 3-Year Average | 10 | $20.52 |
-4%
|
| 5-Year Average | 10 | $20.53 |
-4%
|
| Industry Average | 2.1 | $4.25 |
-80%
|
| Country Average | 3 | $6.25 |
-71%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$1.1B
|
/ |
Jan 2026
$96.2m
|
= |
|
|
$1.1B
|
/ |
Dec 2026
$115.2m
|
= |
|
|
$1.1B
|
/ |
Dec 2027
$135.7m
|
= |
|
|
$1.1B
|
/ |
Dec 2028
$165m
|
= |
|
|
$1.1B
|
/ |
Dec 2029
$202.4m
|
= |
|
|
$1.1B
|
/ |
Dec 2030
$250m
|
= |
|
|
$1.1B
|
/ |
Dec 2031
$312.8m
|
= |
|
|
$1.1B
|
/ |
Dec 2032
$388.8m
|
= |
|
|
$1.1B
|
/ |
Dec 2033
$495.1m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
BioLife Solutions Inc
NASDAQ:BLFS
|
1B USD | 10.4 | -236.8 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 9.9 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 3.8 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 4.1 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 3.1 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 2.9 | 32.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 2 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 6.5 | 50.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
36.7B CNY | 8 | 23.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | 94.9 | -36.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
BioLife Solutions Inc
Glance View
BioLife Solutions Inc., hailing from Bothell, Washington, tells a story of innovation within the niche yet critical biopreservation industry. Emerging as a vital player for cell and gene therapy developers, BioLife Solutions specializes in creating hypothermic storage and transport media tailored for fragile biologic material. Their cornerstone products, like CryoStor and HypoThermosol, are formulated to prolong the shelf-life and viability of cells, tissues, and organs during storage and transportation. These solutions are designed for ultra-cold environments, ensuring the cellular integrity required by biopharmaceutical companies and research institutions engaged in the leading-edge development of regenerative medicine. The company's business model is centered around both direct sales and strategic partnerships. By deeply embedding its proprietary preservation media into clinical-grade processes, BioLife Solutions establishes itself as an integral component of its clients' supply chains. In doing so, the company generates revenue not just from initial sales of its products, but from ongoing usage as therapies move through development pipelines into mainstream clinical applications. Additionally, their diversification into automated thawing devices and personalized medicine services bolster recurring revenue streams, positioning them strategically in an expanding market driven by technological advancements in cellular therapies. Thus, BioLife Solutions stands firmly at the confluence of innovation and necessity, drawing strength from its strategic foresight and commitment to preserving the future of medicine.
